Aquestive Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 11, 2026, reporting its financial results for the second quarter ended June 30, 2026, and disclosing an investor presentation furnished under Regulation FD.

Key Highlights

  • Reporting period: Second quarter ended June 30, 2026
  • Filing date: August 11, 2026, signed by Chief Financial Officer A. Ernest Toth, Jr.
  • Dual disclosure: The filing covers both Results of Operations (Item 2.02) and a Regulation FD investor presentation (Item 7.01)
  • Exhibits attached: A press release (Exhibit 99.1) and Q2 earnings supplemental materials (Exhibit 99.2) are incorporated by reference
  • Exchange listing: Common Stock, par value $0.001 per share, trades on the Nasdaq Global Market under the symbol AQST (NASDAQ:AQST)
  • Not filed for Section 18 purposes: The filing states that information in Items 2.02 and 7.01 "shall not be deemed to be 'filed' for purposes of, or otherwise subject to the liabilities of Section 18 of the Exchange Act"

Aquestive Therapeutics Furnishes Q2 Earnings Materials and Investor Presentation

Aquestive Therapeutics, Inc., a Delaware-incorporated pharmaceutical company headquartered at 30 Technology Drive in Warren, New Jersey, filed this current report to announce second-quarter 2026 financial results and to furnish supplemental investor materials. The company's common stock carries a par value of $0.001 per share and is listed on the Nasdaq Global Market. The report was signed by Chief Financial Officer A. Ernest Toth, Jr.

Under Item 2.02, the company disclosed that a press release announcing reported financial results for the second quarter ended June 30, 2026, along with attached financial schedules, was filed as Exhibit 99.1. The filing noted that the press release also included "an update on recent developments in its business," according to the disclosure. The financial details themselves are contained within the exhibit and are incorporated by reference into the current report.

Under Item 7.01, the company furnished an investor presentation described as materials to be used "at meetings with institutional investors, analysts and others," according to the filing. The filing stated that this information "may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means." The investor presentation is attached as Exhibit 99.2 and is captioned "Aquestive Therapeutics, Inc. Q2 Earnings Supplemental Materials dated August 11, 2026."

What Was Disclosed

Aquestive Therapeutics filed this current report on August 11, 2026, to report second-quarter 2026 financial results via an attached press release and to furnish a supplemental investor presentation under Regulation FD. Both exhibits are incorporated by reference into the respective items but are not deemed filed for Section 18 purposes.